Stage IVC Laryngeal Verrucous Carcinoma: Clinical Trials

2 trials for Stage IVC Laryngeal Verrucous Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow Stage IVC Laryngeal Verrucous Carcinoma: new trials by email Literature Review of Stage IVC Laryngeal Verrucous Carcinoma trials Research Report on Stage IVC Laryngeal Verrucous Carcinoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Phase 2TerminatedNational Cancer Institute (NCI)62014-03-012017-05-03
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)862010-11-012017-03-27

Narrower conditions

Lymphoid Interstitial Pneumonia (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Tongue Neoplasms (2)  ·  Salivary Gland Neoplasms (1)

Broader conditions

Carcinoma (2)  ·  Carcinoma, Squamous Cell (2)  ·  Head and Neck Neoplasms (2)  ·  Mouth Diseases (2)  ·  Mouth Neoplasms (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Stomatognathic Diseases (2)  ·  Tongue Diseases (2)  ·  Salivary Gland Diseases (1)

Interventions

1,2-diaminocyclohexaneplatinum II citrate (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Platinum (1)  ·  Sirolimus (1)  ·  adavosertib (1)  ·  temsirolimus (1)

Sponsors

National Cancer Institute (NCI) (2)

Countries

Canada (1)  ·  China (1)  ·  United States (1)

Top investigators

Eric Winquist (1)  ·  Tanguy Seiwert (1)

NIH funding

N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA014599 (1)